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1. SUMMARY 
 
Post-transcriptional regulation is emerging as a fundamental step in gene expression that, when 
altered, can contribute to carcinogenesis. To identify potentially altered translational networks in 
glioblastoma multiforme (GBM), the worst of brain tumors, we correlated genomic alterations and 
mRNA levels of RNA-binding proteins (RBPs) in 372 publicly available GBM samples and 
identified 56 RBPs whose copy number alterations correlate with their altered expression levels in 
at least 15% of the samples. Among the genes identified using our parameters, HuB (ELAVL2) 
was deleted in 48% of the samples and down-regulated in more than 90% of these. Given the 
evidence for HuB activity as a differentiation factor in neuronal cells, we hypothesized that it may 
act as an oncosuppressor. However, ELAVL2 maps to the same chromosomal band (9p21.3) as 
CDKN2A, the most frequently inactivated oncosuppressor in gliomas, giving the possibility that 
ELAVL2 loss is simply a consequence to the CDKN2A deletion and therefore a passenger, albeit 
very frequent, mutation. To test this possibility, we analyzed the structure of the deletion spanning 
the two loci by qPCR analysis of 233 GBM samples, testing for the presence of the intervening 
region, and we obtained evidence that two independent focal deletions occurred in about 20% of 
the GBM samples bearing homo- and/or heterozygous deletion at CDKN2A and ELAVL2. This 
result highlights that, in rare but recurrent cases,  ELAVL2 deletion occurs independently from 
CDKN2A deletion, supporting the hypothesis that loss of HuB activity is a condition contributing 
to tumor progression. This hypothesis was tested using U87MG cells, a commonly used glioma cell 
line homozygously deleted for CDKN2A and heterozygously deleted for ELAVL2 and primary 
glioma initiating cells (GICs) homozygously deleted for both genes. Migration, invasion and 
capacity to form nuerospheres were determined in U87MG cells upon HuB silencing and 
overexpression, and in GICs upon HuB expression. HuB expression in both cell models resulted in 
a decreased in migration, invasivity and the capacity to form neurospheres, supporting the 
hypothesis that HuB act as a tumor suppressor. We finally showed that HuB is able to determine an 
increase of p21 protein in normal murine neuroblast cells, providing a possible mechanism for 
HuB-mediated suppression of glioma cell clonality. 
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2. INTRODUCTION 
2.1 Glioblastoma 
Glioblstoma multiforme (GBM) is the most frequent and aggressive type of glioma, a class of 
tumors arising from glia or their precursor in the human central nervous system. Also named 
glioblastoma by the World Health Organization (WHO), it is a IV grade of astrocytoma,  a tumor 
associated with a dismal prognosis (1). The current standard of care for GBM is surgical resection 
followed by radiotherapy adjusted with the addition of temozolomide, an oral alkylating agent 
demonstrated to have an anti-tumoral activity in the treatment of recurrent glioma, with a 
statistically significant survival benefit and a minimal additional toxicity. Despite the use of this 
drug, the median survival is only 15 months ( 2, 3, 4 ). On the basis of clinical presentation, GBM 
has been categorized into two groups: “primary” and “secondary” (5). The majority of primary 
GBMs cases (90%) develop rapidly de novo, and  at diagnosis appear as advanced cancers without 
clinical or histological history of a precursor lesion (5, 6). Tumors that have clinical, radiologic, or 
histopathologic evidence of malignant progression from a pre-existing lower grade tumor are 
considered secondary GBMs. Secondary GBMs occur less frequently (5% of GBMs) and 
predominantly in younger patients: the median age of these cancers is ~ 45 years versus ~ 60 years 
for primary GBMs. Despite these differences, secondary and primary GBMs are indistinguishable 
from a histopathologic point of view and the prognosis does not differ after adjustment for age (6, 
7). Focusing on the identification of genetic alterations in GBMs helped to redefine differences 
between the two groups. Loss of 10q heterozygosity (70% of cases), EGFR amplification (36%), 
 p16
INK4a
 deletion (31%), and PTEN mutations (25%) are peculiar of primary GBMs. Whereas 
TP53 mutations are the most frequent in the pathway of secondary GBMs. A recent study 
published by Parada et al. (8), confirmed previous data from Parson et al., indicating that the 
majority of GBMs have alterations in p53, RB and the RTK pathways (9, 10). Alterations in these 
three pathways fuel cell proliferation and enhance cell survival by dysregulating cell-cycle 
checkpoints, induction of senescence or apoptosis (Figure 1) .  
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Figure 1: Core signaling pathways in glioma tumorigenesis. The receptor tyrosine kinase (RTK), 
p53, and Rb pathways are the core signaling pathways in glioma tumorigenesis. Red ovals indicate 
oncogenes that are either overexpressed or amplified in GBM samples, whereas blue ovals 
indicate tumor suppressor genes that are somatically mutated or deleted (except for p27 and 
p21). Source: Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells (8). 
  
 
A widely accepted model for glioblastoma tumorigenesis assumes that this tumor arises from 
developmentally arrested progenitor cells localized in niches, such as the subventricular zone 
(SVZ) (111). Neural cells in the mouse SVZ include: a layer of ependymal type E ciliated cells 
facing the ventricle, relatively quiescent type B cells, which are responsive to growth factors such 
as EGF and PDGF, and give rise to transient amplifying type C cells, which in turn give rise to type 
A neuroblasts that contribute to the rostral migratory stream in most cases, forming olfactory bulb 
mature neurons (Figure 2. A). Cell proliferation in the niche is controlled by the RB1 signaling 
pathway (101). RB1 prevents E2F from promoting  the G1/S transition, unless it is phosphorylated 
by the cyclin D-CDK4/6 and/or the cyclin E-CDK2 complexes. These two complexes are inhibited 
by the cyclin-dependent kinase inhibitor p16INK4A (encoded by CDKN2A, located on 
chromosome 9) and p21 WAF1/CIP1 (encoded by CDKN1A, on chromosome 6), respectively 
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(Figure 2 B). Although it is possible that type B, type A or even putative astrocyte precursor cells 
could give rise to glioblastoma, type C cells are predominantly implicated in the origin of this kind 
of tumor (56, 57, 58). 
 
Figure 2 : The subventricular zone (SVZ), the niche of germinal centres in the brain.  (A) Cells 
populating the SVZ. Neural Progenitor Subtypes in the Subventricular Zone (Top). Coronal section 
through the postnatal adult mouse forebrain depicts subventricular zone (SVZ) progenitors in situ 
including type B (blue), C (amber), and A (green) cells, as well as ciliated ependymal cells (pink) 
that line the lateral ventricle (see 56 for further reading). (Bottom) (B) RB pathway regulates cell 
proliferation in the niche. The two tumor suppressors p16 and p21 block the complexes cyclinD-
CDK4/6 and cyclin-E/CDK2, respectively, which in turn prevents RB from blocking  E2F. In this way 
E2F can induce the G1/S transition. Source: Glioma stem cells: a midterm exam (102) 
 
A widely considered model for tumor formation hypothesizes the existence of cancer stem cells 
(CSCs), able to give rise to other types of malignant cells in the same way that normal stem cells do 
(11,12,13). CSCs are a sub-population in the tumor with self-renewal capacity which are able to 
generate all the heterogeneous cell types constituting the tumor (14). Glioma cancer stem cells 
(GSCs), isolated from human solid tumors(15, 16), share remarkable similarities with normal stem 
cells (NSC), expressing neural stem/progenitor cell markers, such as Nestin, Sox2 and Olig2. 
Moreover, GSCs can be differentiated in vitro to cells expressing neuronal or glial markers.  
NSC resides in a specific region of the brain called niche, which is formed by the subventricular 
zone (SVZ) and the subgranular layer (SGZ) (17). In these regions, specific cells, such as 
ependymal cells and endothelial cells, cytoskeletal proteins and growth factors create a 
microenvironment providing support for the multi-potency and self-renewal of NSC. The same 
could be true for GSC (18). Germinal regions, such as SVZ, have been long suspected to be a 
possible source of gliomas (59, 60). Unsurprisingly, many gliomas are either periventricular or 
contiguous to the ventricular or sub-ventricular zone  (61), and contain cells sharing phenotypic 
and behavioral characteristics with NSCs. Moreover, this subpopulation of cells within human 
10 
 
glioblastoma, exhibits a lower frequency of cell division, compared to the tumor cells, and also an 
enhanced ability to form tumors in vivo: features that are consistent with a tumor-initiating cell. 
They also possess the characteristic of long-term proliferation, self-renewal, generation of different 
progeny, and express the transmembrane glycoprotein prominin 1 (also known as CD133). As 
CD133 positive cells have been demonstrated to be efficient at initiating tumors, including human 
glioblastoma tumors, recent studies proposed to use CD133 as a marker for tumor initiating cells ( 
19- 21).  
 
2.2 ELAVL proteins  
For many years, gene regulation was believed to be controlled primarily at the transcription 
initiation level, the first step in the flow of information from genome to proteome (22). More 
recently however, comparisons between the transcriptone, translatome and proteome indicate that 
gene regulation is largely dependent on complex networks of signals acting on mRNAs, which 
shape the proteome by changing mRNA accessibility to translation. Post-transcriptional regulation 
is controlled by an array of RNA binding proteins (RBPs) and non-coding RNAs and allow a rapid 
adjustment of the cell to environmental changes (23, 24). 
Many proteins that regulate cell growth and differentiation are codified by unstable mRNAs, often 
characterized by cis-regulatory elements responsible for their degradation. One class of such 
elements is represented by the AU-rich elements (AREs) mainly present in 3’ UTRs and bound by 
many RBPs, including members of the ELAVL family (25, 34). 
The embryonic lethal abnormal vision (ELAV) gene, originally discovered in Drosophila, is 
essential for the development and maintenance of the nervous system (26, 62, 63). Vertebrates have 
four, highly-conserved (27-31), ELAV-like (ELAVL) proteins (also referred to as Hu proteins) 
belonging to the RNA-binding protein family of ARE-binding factor, a subfamily of the RNA 
recognition motif (RRM) superfamily. ELAVL1 (HuR/A) is expressed in all cell types and 
localizes primarily to the nucleus. Upon certain cellular signals (like stress signals) ELAVL1 
shuttles to the cytoplasm, where it promotes translation of target mRNAs by mechanisms not 
entirely understood (35). The three other ELAVL proteins—ELAVL2 (HuB/Hel-N1), ELAVL3 
(HuC), and ELAVL4 (HuD)—were discovered as auto-immune antigens in a neurological disorder 
termed paraneoplastic encephalomyelophaty (32) and are almost exclusively expressed in neurons 
(36). These three proteins are collectively referred to as neuronal ELAVL (nELAVL) proteins and 
localize predominantly to the cytoplasm, but they too have the ability to shuttle between nucleus 
and cytoplasm (33). ELAVL proteins have been involved in the regulation of all steps of RNA 
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metabolism, from pre-mRNA splicing to transport, stability and translation (64, 65) suggesting that 
they might act through different mechanisms. 
The ELAVL proteins share both sequence and domain conservation. In mammals, the four 
members are 70-85% identical at the amino acid level. Structurally, they all contain three RRMs, 
each of about 90 amino acids, and a variable hinge region. RRM1 and RRM2 are located one next 
to the other at the N-terminus, whereas RRM3 maps at the C-terminus and is separated from the 
other two by a highly variable hinge region (Fig. 3). RRM3 is able to bind the poly(A) sequence 
and to preserve the stability of RNA-protein complexes. Interestingly, the length of the poly(A) tail 
seems to correlate with efficiency of the binding of ELAVLs to their mRNA targets.  For instance, 
HuD has a ~10 fold higher binding affinity for its target GAP-43 long tail versus short tail (66).  
RRM1 and RRM2 are instead important for binding to ARE sequences present in target RNAs (37- 
41). The hinge region, which varies between the different members of the family, seems to be 
necessary for shuttling the proteins between nucleus and cytoplasm. For example, in the hinge 
region of HuR are present both a nuclear localization signal and a nuclear export signal (67). 
 
 
 
Figure 3: ELAVL protein domains and their function. Not in scale. 
 
ELAVL proteins preferentially bind AU-rich elements (AREs) sequences, although they share a 
high affinity also for other consensus sequences endowed with U-rich, C-rich and GU-rich 
nucleotides ( 42-45). About 5-8% of human genes contains AREs, usually located in 3’UTRs, but 
also in 5’UTRs and/or in coding sequences (46), acting as instability elements (47). In most cases, 
ELAVL binding to these regions increase the expression of the target mRNA (48). Recent studies 
found that ELAVL proteins can also bind ARE or U/GU-rich sequences belonging to intronic 
regions (43-45), suggesting a possible involvement of these proteins in splicing events. In many 
instances, binding of ELAVL proteins to their target mRNAs, do not affect mRNA turnover, but 
promote the recruitment of the target mRNA to polysomes, which leads to an increase in their 
translation. For example, HuR enhances the translation of cytochrome c and p53, and HuB 
increases the translation of neurofilament M (68-70), without changing the levels of the 
corresponding mRNAs. In some cases, ELAVL proteins can also act by stabilizing the target 
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mRNAs in addition to promoting the recruitment to polysomes.  For example, HuB binds and 
stabilizes the glucose transporter (GLUT1) mRNA, but also promote the formation of translation 
initiation complexes (71).  Finally, ELAVL proteins may act as repressors of translation on some 
targets. This is the case for HuR and HuD that suppress p27 translation by inhibiting IRES-
mediated initiation (72).  
A partial list mRNA targets for ELAVL proteins is reported in Table 1, indicating the activity 
exhibited for each targets. The identities of the mRNA targets for the nELAVL proteins highlight 
their roles in the neuronal differentiation program: transcription factors active in neuronal lineage 
(c-fos, c-myc, N-myc, Id), microtubule markers for neuronal development (tau, neurofilament M), 
determinants of neurite outgrowth and synapse formation (GAP-43, neuroserpin) and regulators of 
neuronal proliferation/differentiation (p21, p27, musashi 1). Several experimental findings 
demonstrated that nELAVL proteins are necessary and sufficient to induce neuronal differentiation 
in vitro models and to trigger neuronal commitment in neural stem/progenitor cells (49, 54).  
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Table 1: Known nELAVL target mRNAs. Source: Defining a neuron: neuronal ELAV proteins (25). 
 
 
 
 
  
Protein Target mRNAs Activity 
HuB c-myc
103
  
 c-fos
103
  
 GM-CSF
103
  
 GLUT1
104
 Increased stability and translation 
 NF-M Increased translation 
 Id
105
  
HuC c-myc
106
  
 VEGF
106
  
HuD c-myc
106,107
  
 N-myc Increased stability and expression 
 c-fos
39
  
 VEGF
106
  
 p21
108
 Increased stability and expression 
 p27 Inhibition of translation 
 acetylcholonesterase
109
 Increased stability  
 GAP-43
110
 Increased stability  
 tau Increased stability  
 neurosperpin
111
 Increased expression 
 musashi-1
112
 Increased stability  
 MARCKS
113
 Increased stability  
 CGRP/calcitonin
114
 Regulation of alternative splicing 
HuR cytocromo c
69
 Increased stability 
 p53
68
 Increased stability 
 p27
71
 Inhibition of translation 
 p21
65
 Increased stability 
 cyclin D
65
 Increased stability 
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2.3 HuB  
Human elav-like neuronal protein 1 (Hel-N1, also known as ELAVL2 or HuB) was cloned by the 
Keene’s laboratory, screening a human fetal brain library with a conserved sequence spanning 
RRM 1 and 2 of the Drosophila elav gene as a probe (34). The gene was mapped to chromosome 
9p21 (124), close (  2 megabases) to the locus of p16 ( CDKN2A), a tumor suppressor often deleted 
in many type of cancers (8). Three transcript variants encoding for two different isoforms have 
been identified (Figure 4). 
 
 
Figure 4: Transcript variants for the human ELVL2 gene. Vertical bars represent exons. Red line 
represents the protein (not in scale). Location of each RRM is reported. Comparison with HuD 
(ELAV_HuD_SF) is shown as a reference, as it is the best characterized member of the nELAVL 
proteins (76). 
 
Transcript variant 1 encodes for the longest isoform (Hel-N1 or isoform a; 359 amino acids), 
whereas transcript variants 2 and 3 differ in the 5’UTR and lack an alternate in frame exon 
compared to variant 1. The resulting isoform (Hel-N2 or isoform b; 346 amino acids) has the same 
N- and C-termini, but lack 13 amino acid residues between RRM2 and 3, compared to isoform a. 
Hel-N2 is expressed in several cultured cellular lines, including neuronal precursors, but is absent 
in mature neurons (REF). 
Both isoforms shares   80% sequence identity with the other members of the ELAVL family (25). 
The protein is well conserved within vertebrates (27-31). The mouse have four ELAVL2 isoforms, 
which share 96 to 99% identify at the amino acid level to the human isoforms. Chicken have three 
ELAVL2 isoforms, which are 96% identical to Hel-N1.  
In vitro RNA binding experiments demonstrated the ability of HuB to bind 3’UTRs of c-myc, c-fos, 
colony-stimulating factor and the Id transcriptional repressor, which is abundantly expressed in 
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undifferentiated neural precursors (34, 64). The protein expression was found to be restricted to the 
nervous system and, unlike HuC and HuD, gonads (34, 27, 64, 73). The subcellular localization is 
mainly cytoplasmic, where the protein is detected in granular particles in the soma and along the 
proximal regions of dendrites (64).  
ELAVL2 is an early marker of neuronal commitment. In situ hybridization experiments performed 
on murine embryos show that HuB is the first nELAVL protein to be expressed, in very early post-
mitotic neurons of the ventricular zone, in the intermediate zone and diminishing in the cortical 
plate, whereas in adult mice it is detectable only in scattered neurons (36, 74). 
 
Overexpression of HuB in several cell lines induces neuronal differentiation (26, 51, 55) and 
ectopic transfection of HuB into human teratocarcinoma NT2 cells induces formation of neurites 
(51). Ectopic misexpression of HuB in the mouse neural tube determines the presence of neuronal 
markers (55). 
ELAVL2 binding to transcription factors involved in neuronal differentiations (c-fos and c-myc) 
and microtubules markers of neuronal development (NF-M; Table 1) suggest an important role in 
neuronal development. 
Experiments with murine neuroblastoma cells show that HuB, as well as HuR and HuD, up-
regulate p21 mRNA expression. The silencing of p21, decreases HuB activity, suggesting that p21 
is its downstream effector for differentiation induction (49).  
 
2.4 ELAV in cancer 
Of all ELAVL proteins, the role of HuR in cancer development has been most extensively studied. 
HuR is associated with poor survival in esophageal cancer (75) and has been involved in sarcoma 
development, binding and degrading the tumor suppressor A20 (76). Moreover, HuR expression is 
found in pancreatic, colon and liver cancer as well as in oral squamous carcinoma cells (77-80). 
Recent studies suggest that anti-HuC and -HuD auto-antibodies are novel differential sero-
diagnostic markers for small cell lung carcinoma (SCLC) (81) and large cell neuroendocrine 
carcinoma (LCNEC) (82). Results on SCLC and carcinoid tissues support the hypothesis that 
alterations of nELAV genes could be involved in the onset and/or progression of a subset of 
neuroendocrine lung tumors (83). 
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3. AIM OF THE THESIS 
To investigate the molecular mechanisms leading to glioblastoma multiforme (GBM), the most 
frequent and aggressive class of tumors arising from glia or their precursors in the human central 
nervous system, we started by correlating copy number alterations commonly found in GBM and 
changes in the expression levels of the correspondent RNA-binding proteins (RBPs). Data mining 
of publicly available resources (TCGA Consortium, 2008) identified 56 RBPs, whose expression 
levels are significantly altered in GBM. Among these, we focused on HuB (ELAVL2/Hel-N1), 
deleted in 48% of the sample and down-regulated in more than 90% of these, because it belong to a 
class of RBPs directly involved in neuronal development. 
The   A  2 gene maps on chromosome  p2 , close (  2 megabases) to the p16 (CDKN2A) gene, 
which codes for a cyclin-dependent kinase inhibitor often deleted in GMB as well as in many other 
cancers (86,101). Considering the relevance of p16 mutations in oncogenenesis, we tested whether 
the deletion of the nearby  ELAVL2 gene was the results of an expansion of the p16 deletion or the 
two mutations arose independently. To this aim, we analysed the region spanning the two genes by 
quantitative PCR (qPCR) using genomic DNAs from a collection of 233 GBM samples collected at 
the Verona Borgotrento hospital (Verona, Italy). Testing the presence of the intervening region 
between the two loci in samples bearing deletions of both ELAVL2 and CDKN2A genes, we found 
an intact intervening region in about 20% of the cases, proving that, in a minority of GBM samples, 
deletion of ELAVL2 is a secondary and independent event from CDKN2A deletion. From these 
results and the fact that HuB is involved in neuronal development, we hypothesized that ELAVL2 
may act as an oncosuppressor, suggesting that its loss might be a required mechanism for tumor 
progression.  To test this hypothesis, two GBM cell models, U87 MG cells and primary glioma 
initiating cells (GICs), both lacking CDKN2A, were used. In U87 cells, which are heterozygously 
deleted for ELAVL2, HuB expression was down-regulated or over-expressed, whereas  in GICs, 
 which are homozygously deleted for ELAVL2, HuB was over-expressed. In these two cell models, 
changes in migration, invasion and capacity to form neurospheres under different levels of HuB 
were determined. 
Finally, it was tested the involvement of HuB in the regulation of p21 in non-tumorigenic, 
immortalized neuroepithelial cells. To this aim, murine HuB (mHuB) overexpression was induced 
in H2b2T cells, which were used as a convenient neuronal progenitor model, and the stady-state 
levels of p21 mRNA and protein were determined. Since we noticed a significant upregulation of 
p21 protein upon HuB overexpression we tested which part of the mRNA for p21 was important to 
mediate this activity. 
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4. MATERIAL AND METHODS 
 
4.1 CELLS CULTURE METHODS 
4.1.1 General procedures 
All cell lines were grown in flasks (Corning, 430641) at 37°C, 5% CO2 and  95% humidity. 
U-87 MG, a human glioblastoma cell line, were cultured in Dulbecco’s modified  agle medium 
(DMEM high glucose; Gibco, 10938-025) supplemented with 10% Fetal Bovin Serum (Lonza, 
DE14-801 F) and  5x10 
4 
U Penicillin/Streptomycin (Lonza, DE17-602 E). 
U-87 were cultured as neurospheres with Neurobasal Medim (Invitrogen, 21103-049) 
supplemented with 20 nM of hrFGF (Sigma, F 0291), 20nM of EGF (Sigma, E 9644) and 10nM of  
LIF (Sigma, L 5283) for 6 days (85). 
H2b2T, an immortalized murine cell line, was cultured in  RPMI 1640 Medium GlutaMAX 
(Invitrogen, 61870-010), supplemented with 5 x 10
4
U Penicillin/Streptomycin  (Lonza, DE17-
602E) and 10% Fetal Bovine Serum (Lonza, DE14-801F). 
 
Human glioblastoma initiating cells (GICs# 030616) were derived from human brain after a 
dissection procedure described in reference (84), and were kindly provided by Dr. Rossella Galli 
(Fondazione San Raffaele Del Monte Tabor, Milan). They were cultured as neurospheres with 
Neurobasal Medium (NeuroCult™ NS-A Proliferation Kit; Stemcell, 05750), supplemented with 
EGF (R&D System, 236-FB), FGF (R&D System, 233-FB) and Heparin (Sigma, H3393) following 
the protocol described in reference 84.  
  
4.1.2 Generation of stable cell lines  
All stable cell lines were created following the Lamia Lab Viral Production and Infection Protocol 
(tronolab.epfl.ch/lentivectors). Briefly, HEK-293T cells were transfected with  0 μg of ΔR (a 
plasmid coding for the virion packaging system), 5μg of  S G (a plasmid coding for the virion 
envelope) and 20 μg of the plasmid of interest. 48 hours post infection the supernatant from the cell 
culture was collected and, together with reverse transcriptase (0.8 U/ml), were added to the cells of 
interest.  
U87 stable lines (indicated as U87 sh-HuB in all figures), were created using an shRNA lentiviral 
vector to silence ELAVL2  (GIPZ Human ELAVL2 shRNA; Thermo Scientific, Clone ID: 
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V3LHS_639120) and pCMV6-AN-GFP (Origene, PS100019) for the control line (U87 sh-CTR in 
all figures). The cells were selectively maintained using 50ug/μl of puromycin (Sigma, P8833). 
 
To generate H2b2T cells stably over-expressing ELAVL2 (indicated as H2b2t st-HuB in all 
figures), HuB_CMVpLenti Dest PURO was used: this vector contains the cDNA of murine 
ELAVL2 (NM_207685.1) transcript variant 2. As a control (H2b2T st-CTR in all figures), 
CMVpLenti Dest PURO (Addgene, 17452) empty plasmid was used. The cells were selectively 
maintained using  00ng/μl of puromycin (Sigma, P8833). 
 
Stable over-expression of ELAVL2 in GICs (indicated as GICs-HuB in all figures) was created 
using pLenti CMV GFP DEST (736-1) (Addgene, 19732), containing the cDNA of human 
ELAVL2 transcript variant 2 (NM_001171195.1); the control (GICs-CTR in all figures) was 
obtained with an LR-CLONASE between pENTR-DsRed2 N1 (Addgene, 22523) and  pLenti 
CMV Puro DEST (Addgene, 17452) . 
 
4.1.3 Transient transfection 
To achieve transient over-expression of ELAVL2, U87 MG cells were transfected with a 
mammalian expression vector for ELAVL2 (indicated as U87-HuB in all figures) or a control 
vector (U87-CTR in all figures). The plasmid used for ELAVL2 over-expression was pCMV6-Neo 
(Origene, pCMV6NEO), containing the cDNA of human ELAVL2 transcript variant 2 
(NM_001171195.1). For generating the control cells, the empty pCMV6-Neo (Origene, 
pCMV6NEO) plasmid was used. Cells were seeded in six-well plates (Corning, 3516), at a density 
of 3 x 10
5
 cells/well or in 100 mm plates (Corning 430167), at a density of 6 x 10
6 
cells/plate. After 
24 hours the medium was replaced with Opti-MEM medium (Life Technology, 11058-021) and the 
cells were transfected. For transfection, two separate solutions were prepared: (a)  0 μl of 
lipofectamine (Invitrogen, 11668-0  ), mixed with 240 μl of medium, and (b) 4 μg of plasmid 
DNA diluted in ~250 μl of medium. Both solutions were left at room temperature for 5 minutes, 
then mixed together and incubated at room temperature for 20 minutes. The final 500μl mixture 
was added to the medium of each well. 4-5 hours post-transfection the cells were visually inspected 
and if the viable cells were at least at 80%, the Opti-MEM was replaced with DMEM. 
In the same way H2b2T cells were transfected with a mammalian expression vector for HuB 
(pCMV6-Entry-HuB) or a control vector (pCMV6-Neo-empty). The cells were sown in a six-well 
plates (Corning, 3516),           for well, or in petri plates (Corning 430167),         for plate. 
24 hours later the medium was replaced with of Opti-MEM medium (Life Tecnology, 11058-021) 
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and the cells were transfected. The plasmid used for HuB over-expression (indicated as H2b2t-HuB 
in all figures) was Elavl2 (NM_207685.1) Mouse cDNA ORF Clone (Origene, MR2  803): “Myc-
DDK-tagged ORF clone of Mus musculus ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 2 (Hu antigen B) (ELAVL2), transcript variant 1 as transfection-ready DNA”. For control cells 
(indicated as H2b2t-CTR in all figures) the empty pCMV6-Neo (Origene, PCMV6NEO) plasmid 
was used.4-5 hours post-transfection the cells were visually inspected and, if the viable cells were 
at least at 80%, the Opti-MEM was replaced with RPMI 1640. 
Table 2 below shows the name used for each type of cell in the different experiments.  
 
 
Table 2:  Acronyms used for each type of cell in the different experiments. 
Cells type Name Feature  
U-87 U87 sh-scr scramble Stable transfection 
 U87 sh-HuB Elavl2 knock-down Stable transfection 
 U87-CTR  mock  Transient trasnsfection 
 U87-HuB  Elavl2 over-expression  Transient trasnsfection 
GICs GICs-CTR scramble Stable transfection 
 GICs-HuB Elavl2 over-expression Stable transfection 
H2b2T H2b2t st-CTR scramble  Stable transfection 
 H2b2t st-HuB Elavl2 over-expression Stable transfection 
 H2b2t-CTR mock  Transient trasnsfection 
 H2b2t-HuB Elavl2 over-expression  Transient trasnsfection 
 
 
4.1.4 Scratch Assay 
U87-shHuB cells and U87-shCTR cells were seeded – 5,0 x 105 per well – in a transparent 6-well 
plate (Costar, 3516), in 2 ml of DMEM (see paragraph 3.1.1) medium. After 24 hours of 
incubation at 37°C, time sufficient to reach confluence, the cells were scraped with a P200 pipet tip 
in a straight line to create a “scratch”. The images were acquired every 60 minutes over the course 
of 7 hours. The test was performed with 6 technical replicates per condition, in 3 different 
biological replicates. 
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4.1.5 Cell Migration and Invasion Assay 
Adherent cells were incubated for 24h at 37°C, time sufficient for them to reach  confluence, after 
which they starved for 8 hours, by means of growning them without FBS. At the end of the 
starvation period, cells were seeded into migration/invasion upper chambers (Millipore, ECM509 
and ECM554 ) in medium without serum. As chemoattractant, in the lower chamber, the medium 
was supplemented with 2% of serum. The size of membrane’s pores were 8 µm. The assay was 
performed using three biological replicates, each of them consisting of three technical replicates. 
 
U87-shHuB cells and U87-shCTR cells were sown – 5,0 x 105 per well – in a transparent 6-well 
plate (Costar, 3516), in 2 ml of DMEM complete medium (see paragraph 3.1.1).After 8 hours of 
starvation, 3,0 x 10
5 
cells were sown in each upper chamber containing 250µl of DMEM without 
serum and, in the lower chamber, 500 µl of DMEM with 2% of serum was supplied. The same 
protocol was used for the transiently transfected cells, U87-HuB and U87-CTR.  
 
H2b2T-stHuB cells and H2b2T-stCTR cells were sown – 3,5 x 105 per well – in a transparent 6-
well plate (Costar, 3516), in 2 ml of RPMI complete medium (see paragraph 3.1.1).Therefore, 
after 8 hours of starvation, 3, 0 x 10
5 
cells were sown in each chamber containing 250µl of RPMI 
without serum and, in the lower chamber 500 µl of RPMI with 2% of serum as chemoattractant. 
 
GICs-HuB cells and GICs-CTR cells were sown – 2.5 x 105 per well – in a transparent 6-well plate 
(Costar, 3516), in 2 ml of Neurobasal complete  medium (see paragraph 3.1.1).After an incubation 
of  5 days at 37°C, time required for nuerospheres formation, the neurospheres were centrifuged at 
1000 x g for 10 minutes and the pellet was re-suspended in 1ml of PBS (Gibco, 10010-015). Cell 
dissociation was achieved by the addition of 1/20
th
 of the resuspension volume of  a 1:1 solution of 
Trypsin (Gibco, R-001-100) and PBS supplemented with  2mM of EDTA (Sigma, E6758), 
followed by repeating pipetting up and down to disaggregate the neourosperes. This cell suspension 
was loaded into the upper chamber and the complete neurobasal medium (see paragraph 3.1.1).was 
used as a chemoattractan in the lower chamber. 
 
4.1.6 Neurosphere assay 
U-87 cells were cultured as neurospheres in 96-well plates (Costar, 3595) for six days. For each 
conditions 10 wells containing 200µl medium with 20 cells/µl were prepared, and only spheres that 
exceeded 100 µm in diameter were considered as neurospheres. Images were captured using an 
21 
 
inverted microscope LEICA DM IL LED and analysed using Leica LAS EZ software (version 
1.5.0, Leica Application Suite). 
GICs derived from the dissociation of neurospheres were seeded in 96-well plate (Costar, 3595), 20 
cells/µl in 200µl were sown in each well (87). Images were acquired using Operetta PerkiElmer 
High content Screening System with a 2X long WD objective, which allows to image an entire 
well. GICs-RED were imaged with 520-550 nm Ex filter and 560-630 nm Em filter, and GICs-GFP 
with 460-490 nm Ex filter and 500-580 nm Em filter. For each condition 10 wells were analyzed 
automatically by Harmony Software. The first step of the image analysis sequence was the 
identification of spheres. After removal of objects touching the border of the well, they were 
further analyzed by measuring their morphology properties. Finally the population of spheres 
having a diameter greater than 100 µm and a roundness greater than 0.8 were selected and counted.     
 
4.1.7 Fluorescent In Situ Hybridization (FISH) 
Paraffin GBM samples, kindly provided by Dr. Andrea  Talacchi and Dr. Claudio Ghimenton 
(BorgoTrento Hospital, Verona, Italy) were prepared in triplicates on slides using Manual Arrayer 
(Beecher Instruments, Micro-Array Technology), and the size of the core was of 1mm in diameter. 
Vysis LSI CDKN2A/CEP 9 Probes Kit was used to identify the presence of CDKN2A. LSI 
CDKN2A (p16) probe was labelled with SpectrumOrange and the CEP 9 probe was labeled with 
SpectrumGreen. The LSI CDKN2A probe spans approximately 222 kb and contains a number of 
genetic loci including D9S1749, DS1747, p16 (INK4B), p14 (ARF), D9S1748, p15(INK4B), and 
D9S1752. The CEP 9 SpectrumGreen probe, hybridizing to alpha satellite sequences specific to the 
centromere of chromosome 9, was used as control for chromosome 9. The presence of ELAVL2 
was analyzed using BAC RP11-110I5 (which covers the entire   A  ” locus)  labeled with 
SpectrumOrange. Nuclei were stained with Dapi (Sigma, D 9542). The analysis was performed in 
blind by 2 groups using Zeiss Axio Observer Z1- Apotome. 
 
4.1.8 Fluorescence Activated Cell Sorting (FACS) 
GICs cells overexpressing ELAVL2 (GICs-HuB) and control cells (GICs-CTR) were sorted using a 
FACSAria cytometer (DB Biosciences, San Diego, CA). The emission filters used were BP 530/30 
for GICs-GFP (FITC) and BP 585/42 for GICs-Red (PE). Between each fluorescence spectrum, 
appropriate values of electronic compensation were adjusted. Debris and duplets were excluded 
from the analysis. Dissociated cells were resuspended in PBS (Gibco, 10010-015), 2mM EDTA 
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and 1% of Penicillin/Streptomycin. Cell suspension was passed through a 30µm filter (Filcons, 
130-33s) and analysed using the FACSAria cytometer. Cell populations were isolated, at room 
temperature, in polystyrene tubes (BD Biosciences, 352054) using a 100µm nozzle aperture, 20 psi 
pressure, with an average of 2000 events/sec. Data were analyzed with FACSDiva data analysis 
software (BD Biosciences), which gave a purity of 96.5% for GICs-Red and 97% for GICs-GFP.  
The CycleTEST PLUS DNA Reagent Kit (BD Biosiences, 340242) was used to analyze the cell 
cycle of GICs cells. About 5 x 10
5
 of cells were used for analysis following the manufacturer’s 
instructions. Briefly, the test was performed after seven days of culture in neurosphere condition. 
The emission filters used were LP 670 for PI (PercP),  BP 530/30 for GICs-GFP (FITC) and BP 
585/42 for GICs-Red (PE). 
 
4.2 MOLECULAR METHODS 
4.2.1 RNA extraction and reverse transcription 
Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen, 73404), which allows for 
elimination of DNA, and quantified using a spectrophotometer (Nanodrop N1000). Reverse 
transcription was performed with 200ng of total RNA using iScript cDNA Synthesis Kit (Biorad, 
170-8890), following the manufacturer’s instructions. 
 
4.2.2 Polysomal and sub-polysomal RNA extraction 
Cells were grown in  00 mm dishes (Corning, 430 67) until they reached       80% confluency. 
Polysomes were stalled by incubating the cells with 10 µg/ml of cyclohexamide (Calbiochem, 
239763) at 37°C for 3-4 minutes. After two washes with 5 ml of ice-cold PBS (Gibco, 10010-015)  
supplemented with 10 µg/ml of cyclohexamide, the cells were treated with 300 µl of ice-cold Lysis 
Buffer (10 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl pH 7.5, 1% Triton-X 100, 1% sodium 
deoxycholate, 0.2 U/µL RiboLock RNase inhibitor, 1 mM dithiothreitol, 0.01 mg/ml 
cycloheximide), scraped with a cell scraper (Sarsted, 83.1832), transferred to a pre-chilled 1.5 ml 
microcentrifuge tube and centrifuged at 16000 x g for 5 minutes at 4 °C to pellet the nuclei. 
After preparation of sucrose gradients and centrifugation of the samples at 197 000 x g in a Sorval 
WX Ultracentrifuge for 1 h 40 min at 4°C, the gradient was fractionated using a Teledyne Isco 
model 160 gradient analyser, equipped with a UA-6 UV/VIS detector, collecting 1 ml fractions. 
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4.2.3 Reverse transcription of polysomal and sub-polysomal RNA 
Each polysomal fraction was digested at 37°C for 1-2 hours with 100 µg/ml proteinase K (Qiagen, 
19131) and 1% SDS (Sigma, L3771). 250 µl of phenol/chloroform/isoamyl alcohol (Sigma, P2069) 
was added to each sample, mixed well and centrifuged at 16 000 x g for 5 minutes at 4°C. 
Subsequently, the upper, aqueous phase was transferred to a fresh tube, 1 ml of isopropanol 
(Sigma, I9516) was added and the samples were placed at -80°C for 1-2 hours. After a 
centrifugation at 16 000 x g for 30-40 minutes, the supernatant was removed and the pellet was 
subjected to purification using RNeasy Plus Mini Kit (Qiagen, 73404). 
 
4.2.4 Extraction of genomic DNA from paraffin samples 
Genomic DNA was extracted from 233 paraffin tissue samples (diagnosed in the 2006-2009 
period) of glioblastoma multiforme (GBM), kindly provided by Dr. Andrea  Talacchi and Dr. 
Claudio Ghimenton (BorgoTrento Hospital, Verona, Italy) and analysed for copy number variation 
(CNV). Samples were first subjected to deparaffination and then the genomic DNA was extracted. 
To remove the paraffin, 1 ml of Xilene (Sigma, 396052) was added to each sample (composed of 
4-6 slides), vortexed for 10 minutes and centrifuged at 16 000 x g for 5 minutes. The supernatant 
was discarded and the procedure was repeated. 1 ml of absolute ethanol (Sigma, 02860) was added 
to each pellet, vortexed for 10 minutes and centrifuged at 16 000 x g for 5 minutes. The supernatant 
was descarded and the ethanol wash repeated once more. After removing the ethanol, 360 µl of 
buffer ATL (Qiagen, 19076) and 40 µl of proteinase K (Qiagen, 19131) were added to the pellets, 
and an overnight incubation in a thermomixer (Eppendorf, thermomixer comfort) at 55°C and 450 
rpm was performed. 
After cooling down the samples, 8 µl of RNAse A (Qiagen, 19101) were added, samples were 
incubated at room temperature for 2 minutes and centrifuged for 30 seconds at 6000x g. 200 µl of 
buffer AL (Qiagen, 19075) were added to the samples and an incubation in thermomixer was 
performed at 70 °C for 10 minutes. The samples were then centrifuged for 30 seconds at 6000 x g. 
200µl of absolute ethanol (Sigma, 02860) were added and the samples were centrifuged for 30 
seconds at 6000 x g. The supernatant was transferred to a DNeasy spin column (Qiagen, 1011707) 
and centrifuged for 1 minute at 6000 x g. The flow-through was discarded, 500µl of buffer AW1 
(Qiagen, 19081) were added to the column and a centrifugation at 6000 x g for 1 minute was 
performed. The flow-through was discarded, 500µl of 80% ethanol were added to the column and a 
centrifugation at 20 000 x g for 3 minute was performed. The column was left for 1 minute at room 
temperature in a new tube with 100 µl of nuclease free water (Qiagen, 129114), then it was 
24 
 
centrifuged at 6000 x g for 1 minute and the amount of gDNA was quantified using a 
spectrophotometer (Nanodrop N1000). 
 
4.2.5 Quantitative PCR with SYBR green 
Primer Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) was used to design 
primers for target genes MECP2, CDKN2A, and ELAVL2, two intervening regions between the 
last two genes (INV1 and INV2) and for two reference genes: SNRPF and CTDSP1. Subsequently, 
a BLAST search (http://blast.ncbi.nlm.nih.gov) was performed to evaluate the specificity of these 
primers which were synthesized by Eurofins MVG Operon. Triplicate wells of simplex (CDKN2A, 
ELAVL2, INV1 and INV2, SNRPF and CTDSP1) reactions containing a series of 10-fold dilutions 
of DNA samples (100-0.01 ng/reaction) were used to determine the PCR efficiency of each primer 
pair, assessed by performing a melting curve analysis of the PCR template. qPCR reactions were 
carried out in triplicate on 384-well reaction plates (Bio-Rad, HSP 3805) with KAPA SYBR FAST 
qPCR MAster Mix (RESNOVA, KK4601), using CFX384 Real-Time PCR Detection System (Bio-
Rad, 185-5384). The qPCR reaction was performed with 15ng of gDNA. Table 3 lists the 
sequences of the oligonucleotides used for this analysis. 
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Table 3:  Primers used in qPCR to detect CNAs on genomic DNA of GBM samples. 
 
 
Oligonucleotides were synthesized by Eurofins MVG (http://www.eurofinsgenomics.eu/). 
Amplifications were performed over 40 cycles, including a denaturation (95°C, 15 seconds), an 
annealing step (60, 20 seconds) and an extension step (72°C, 1 minute). Each reaction was 
performed including an internal control consisting of the gDNA from the same pool of samples, but 
with a normal copy number of the region studied. The results were obtain using the 2 
–ΔΔCt 
method. 
Data acquisition and the analysis of the qPCR assays were performed using CFX Manager 
TM 
Software 184-5000 (Version 3.0, Bio-Rad). 
 
4.2.6 qPCR with TaqMan probes 
Analysis of stemness (SOX2 and NESTIN,) of p21 and ELAVL2 genes were performed using 
Taqman probes. Probes were supplied by Life Technologies (http://www.invitrogen.com). The 
probes used for these validations are reported in the Table 4. 
Primer 
name 
Accession Position Sequence Amplicon 
size 
Primer 
concentration 
[FINAL] 
MECP2 f 
r 
NT_167198.1 chrX: 
 4,215,430- 
4,215,347 
GAGTGGGAAGTTCTCAAGGTAGCA 
TGCTTCCGCAGCTATTCCA 
84 200nM 
200nM 
CDKN2Af 
r 
NT_008413.18 chr9: 
21,958,172-
21,958,276 
CTTCGGTGACTGATGATCTAAGTTTC 
GTTTCTAACGCCTGTTTTCTTTCTG  
105 400nM 
400nM 
ELAVL2 f 
r 
NT_008413.18 chr9: 
23,725,162-
23,725,243 
AAAAATTTGCCTGGTAACTGAACAT 
TGACCACAGGTAGCTTCTGAGAAT 
82 400nM 
400nM 
INV1    f 
r 
NT_008413.18 chr9: 
22,742,705-
22,742,798 
TGGAGGCAGAGCTGAGGAAT 
GAAGGCTCAAGATTTTGTTCTCATC 
94 400nM 
400nM 
INV2    f 
r 
NT_008413.18 chr9: 
23,428,171-
23,428,275 
CTATAAGCAAGGAGCCAAGATATGC 
GGTTGGAGTAGAACCCCACTGA 
105 400nM 
400nM 
SNRPF  f 
r 
NT_029419.12 chr12: 
58,396,439-
58,396,542 
AGAATTTGCACTTCCCACTTAACC 
TGTCTTCCCCACCCAAGTGA 
104 400nM 
400nM 
CTDSP f 
r 
 
NT_005403.17 
 
chr2: 
69,476,893-
69,477,005 
CCCCTGGATTCCTGCACTAG 
CCGCCAGAAAACGATCAAAAC 
113 400nM 
400nM 
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Table 4: Taqman probes used to quantifying mRNA level with qPCR. 
(Abbreviations: Mm= mus musculus, Hs= Homo sapiens). 
 
 
 
 
 
 
 
 
 
 
 
All probes were labelled with FAM report dye. The qPCR reaction was performed with 10ng of 
cDNA, with KAPA Probe Fast Universal qPCR Kit (R SNO A, KK4702), using manufacturer’s 
instructions. Amplifications were performed over 39 cycles, including a denaturation (95°C, 3 
seconds), an annealing step (60, 20 seconds) and an extension step (72°C, 1 second), using CFX96 
Real-Time PCR Detection System (Bio-Rad, 185-596). The analysis was performed on 96-well 
reaction plates (Bio-Rad, HSP 9645) in three biological replicates, each performed in three 
technical replicates, using 2 
–ΔΔCt 
method. Data acquisition and the analysis of the qPCR assays 
were performed using CFX Manager 
TM 
Software 184-5000 (Version 3.0, Bio-Rad). 
 
4.2.7 Microarray analysis 
Total and polysomal RNA, obtained as described in the chapter (3.2.1-3.2.3), was hybridized on 
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F, following Agilent protocol 
“One- Color Microarray-Based Gene  xpression Analysis (Quick Amp  abeling)”.  
The hybridization results were analysed using the product of the ranks (Rank Product, RP), 
developed by Breitling et al., 2004 (126). Significant results (P-value <0.01) were clustered 
TARGET CODE 
P21 Mm04205640_g1 
SOX2 Hs01053049_s1  
NESTIN Hs00707120_s1 
ELAVL2 Hs00270011_m1 
Mm00516015_m1 
REFERENCE 
GENES 
CODE 
TBP Hs00427620_m1 
Mm00446973_m1 
HPRTI Hs01003267_m1 
Mm00446968_m1 
B2M Hs00984230_m1 
Mm00437762_m1 
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hierarchically using the database DAVID (Database for Annotation, Visualization and Integrated 
Discovery) Bioinformatics Resources 6.7 .Analysis was performed in two steps. First, all the genes 
that were differentially expressed (Differential Expression Genes – DEGs) between a condition of 
control and a condition of treatment were extracted. Then, the genes differentially expressed 
between total mRNA and polysomal mRNA samples were determined. 
 
4.2.8 Luciferase assay 
In order to determine the linear range of DNA concentration for the luciferase assays, H2b2T-HuB 
were transfected with several concentration of either the firefly luciferase plasmid (pGL4.13) or 
each of the tested reporter plasmids (see section 3.8 Plasmid construction). The concentrations 
tested were: 0,04; 0,06; 0,08; 0,1; 0,12 µg. This initial screen revealed that 80 ng of DNA was the 
best concentration for the assay. The Renilla luciferase plasmid, pGL4.74 (Promega, E6921), was 
co-transfected after first screening revelation of the best concentration needed, that was 30 ng of 
DNA. The plasmid was used as control in order to eliminate any apecific response, which is not 
dependent on the inserts. 
Luciferase assays were performed using the Dual-GloLuciferase Assay System (Promega, E2940) 
24 and 48 hours after transfection. 
The experimental results ( ) was obtained with the formula: 
  
                       
                       
 
then for each   value the error Δ  was calculated as the Stardard Deviation of the mean of each 
sample Firefly/Renilla ratio  
 
4.2.9 Plasmid construction 
To test whether the regulation of p21 mediated by mHuB occurs via the p21 UTRs, three plasmids 
were created (Fig 4), in which the coding region of a luciferase reporter gene was flanked by: 
1) The 3’UTR of murine p2  plus an unrelated 5’UTR; 
2) The 5’UTR of murine p2 , variant  , plus an unrelated 3’UTR; 
3) The 5’UTR of murine p2 , variant 2, plus an unrelated 3’UTR; 
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Figure 5: structures of the created plasmids  
 
The parental plasmid for cloning the p21 UTRs was pGL4.13 (Promega, E668A), which encodes 
the luciferase reporter gene Luc2 (derived from Photinus pyralis) under the regulation of the strong 
SV40 early enhancer/promoter. This gene is engineered to be condon-optimized for mammalian 
expression and consensus sequences for transcription-binding sites has been removed from 
regulatory regions. Therefore, the vector is designed for high expression and reduced anomalous 
transcription in mammalian cells and can be used as an expression control or a co-reporter vector. 
 
4.2.10-1 Generation of pGL4.13-p21-5’UTR-v1 and pGL4.13-p21-5’UTR-v2 
To generate the pG 4. 3 plasmids containing the p2  5’UTRs we used the following two gBlocks 
Gene Fragments (purchased from IDT), which contains the two variants of p2  5’UTR (highlighted 
in blue) flanked by HindIII sites (bolded and underlined): 
              >p2 _v _5’UTR 
TAGCCGATATCAACAGAGTATACCAAACGGTTTGATATCGCAAGCTTAGC
AGCCGAGAGGTGTGAGCCGCCGCGGTGTCAGAGTCTAGGGGAATTGGAGT
CAGGCGCAGATCCACAGCGATATCCAGACATTCAGAGAAGCTTGCGG 
>p2 _v2_5’UTR 
TAGCCGATATCTAACGTAGTAATAAACGGTTTGATATCGCAAGCTTGGTGG
TGGAGACCTGATGATACCCAACTACCAGCTGTGGGGTGAGGAGGAGCATG
AATGGAGACAGAGACCCCAGATAATTAAGGACGTCCCACTTTGCCAGCAG
AATAAAAGGTGAAGCTTGCGGC 
 
Each gBlocks was digested with HindIII-HF (NEB, R3104S) and ligated to the parental vector 
previously restricted with the same enzyme and dephosphorylated with Antarctic Phosphatase 
(NEB, M0289S). Ligation products were used to transform XL1-Blue competent cells (Stratagene, 
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200249) and the plasmid DNA of several individual transformants was extracted using a standard 
method (Maniatis and Sambrook, 1982). To test for the presence of an insert, the plasmid DNA 
from individual transformants, along with a sample of the parental vector (which served as a 
negative control), were digested with ApaI and BglII. To test for the direction of the inserts, clones 
containing a single insert for the 5’UTR variant   were digested with EcoRV and BglII (EcoRV is 
present once in the v  insert; bolded), whereas clones containing a single insert for the 5’UTR 
variant 2 were digested with MseI (MseI is present once in the v2 insert; bolded). 
Presence and orientation of the inserts were confirmed by DNA sequencing, using the following 
primer: 
Lux-5’rev  5’-CTGCTCGCCGGCGGTCC-3’ 
 
4.2.10-2 Generation of pGL4.13-p21-3’UTR 
To generate a pGL4.13 plasmid containing the mouse p2  3’UTR, we first PCR-amplified the 
mouse p2  3’UTR from mouse spinal cord cDNA (kindly provided by Daniele Peroni) using the 
following two primers (XbaI sites are underlined):  
 
p2 _3’UTR_Fw 5’-GCGCTCTAGATTTCTATCACTCCAAGCGCAGATTGG-3’ 
p2 _3’UTR_Rv 5’-GCGCTCTAGATCATCGAGAAGTATTTATTGAGCACCAGC-3’ 
 
For the PCR reaction, it was used: 100 ng of DNA template, 1.5 µl of each primer (100 mM stock) 
and 5 units of high-fidelity AccuPrime Taq DNA Polymerase (Invitrogen, 12346-086) in the 
presence of the appropriate buffer. The PCR program was optimize as follow: 
 
Start: 95°C for 120 sec  
Denature: 95°C for 30 sec, 
Anneal: 61°C for 30 sec 
Extend: 68°C for 105 sec 
34 cycles 
End: 68°C for 180 sec. 
 
 
After amplification, the sample was then resolved on a 1% agarose gel and the  1.4 Kb DNA 
fragment was gel-purified using the Wizard SV Gel and PCR Clean-Up System (Promega, A9282). 
The gel-purified DNA fragment was digested with XbaI and ligated to a pGL4.13 vector previously 
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restricted with the same enzyme and dephosphorylated with Antarctic Phosphatase (NEB, 
M0289S). Ligation products were used to transform XL1-Blue competent cells (Stratagene, 
200249) and the plasmid DNA of several individual transformants were extracted using a standard 
method (Maniatis and Sambrook, 1982). To test for both presence and orientation of the insert, 
plasmid DNA from individual transformants were restricted with EcoRV (EcoRV is present once 
in the parental vector and once in the 3’UTR close to one of the ends). The insert from two positive 
clones were completely sequenced using the following two sequencing primers:  
 
 uc_3’  5’-CCGCGAGATTCTCATTAAGGCC-3’ 
S 40_5’ 5’-GGTTTGTCCAAACTCATCAATGTATC-3’ 
 
4.2.11 qRT-PCR of H2b2T cells steadily expressing HuB 
SYBR Green DNA-binding dye was used to detect p21 mRNA levels in H2b2TstHuB stable cell 
line. The primers used for the analysis where created taking into account that longer amplicons 
generate stronger signals (Arya et al., 2005). Thus all have about the same short length, and were: 
 
p2 _3’UTR_Fw    5’-GCCTTAGCCCTCACTCTGTG-3’ 
p2 _3’UTR_Rw   5’-AGGGCCCTACCGTCCTACTA-3’ 
 
p21_CDS_Fw   5’-CGGTGGAACTTTGACTTCGT-3’ 
p21_CDS_Fw   5’-AGAGTGCAAGACAGCGACAA-3’ 
 
p2 _5’UTRv2_Fw   5’-GGGTGAGGAGGAGCATGAAT-3’ 
p2 _5’UTRv2_Rw   5’-TATTCTGCTGGCAAAGTGGGA-3’ 
 
p2 _5’UTRv _Fw   5’-CGGTGTCAGAGTCTAGGGGAA-3’ 
p2 _5’UTRv _Rw   5’-GTGCCTGTGGCTCTGAATGT-3’ 
 
For this analysis the primers were designed in order to cover specific regions of p21 transcripts 
(5’UTR, CDS and 3’UTR), which were not available as Taqman probes. The primers were 
designed with Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and 
verified with BLAST (http://blast.ncbi.nlm.nih.gov/). Primers were used at concentration of 
200nM. Efficiencies were between 98 and 100 % slopes between -2,9 and - 3,1, and R2 near 1. The 
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housekeeping gene used was ribosomal protein L41 gene (courtesy of Giovanni Provenzano). Four 
biological replicates were analysed. For each biological replicate, 3 technical replicates were tested. 
The reaction mix for each well contained: 
 
Components     Volume per well 
2x Kapa Sybr     5 μl 
Forward primer (200nM)    0,2 μl 
Reverse primer (200nM)    0,2 μl 
cDNA (5 ng/μl)     2 μl 
Millipore H2O for Molecular Biology  2,6 μl 
Total volume      10 μl 
 
The termocycler used was the CFX96 Touch Real-Time PCR Detection System(Bio-Rad, 185-
5196). 
4.3 PROTEIN METHODS 
4.3.1 Immunoblotting analysis  
Cells were harvested after 48h with a scraper (Sarstedt, 831832). RIPA buffer (50 mM Tris HCl pH 
7,4; 150 mM NaCl; 1 mM MgCl2; 0,1 %TritonX100) supplemented with, 1/100
th
 phosphatase 
inhibitor cocktail 1 and 2 (Sigma, P0044 and P5726), Pepstatin A (Sigma, 77170; 1:1000 final 
dilution) and protease inhibitor cocktail (Sigma, P834; 1:200 final dilution),was used as lysis buffer 
to extract proteins. 300µl of lysis buffer were added to each samples, three freezing-thawing cycles 
(in liquid nitrogen and at 37°C, 5 minutes each cycle) were performed followed by a centrifugation 
at maximum speed for 30 minutes. Total protein concentration was determined using the Bradford 
assay (Sigma, B6916) using BSA as a protein standard. For each sample, 10 µg of total protein 
were subjected to 10% SDS-Tris glycine polyacrylamide gel electrophoresis and transferred to a 
nitrocellulose membrane (Bio-Rad, 162-0112). The membrane was blocked with 5% nonfat milk 
(Santa Cruz, sc2325) in TBS-Tween buffer [10mM Tris (pH7.5), 100mM NaCl, 0.1% Tween 20 
(Sigma, P2287)] and incubated with primary antibodies for 1h at room temperature. The same 
incubation was performed with the secondary antibodies. Detection of immunocomplexes was 
performed using the ECL system (GE Healthcare, RPN2232). Normalization was done using 
GAPDH or β-tubulin. The antibodies used in this study are reported in Table 5. 
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Table 5: Antibodies used for WB analysis. 
Protein targeted Code of Antibody Dilution 
P21 sc-397, Santa Cruz 1:200 
ELAVL2 14008-1-AP, Proteintech 1:3000 
Reference proteins Code of Antibody Dilution 
Β TUBULIN sc-53140, Santa Cruz 1:1000 
 
 
4.4 STATISTICAL ANALYSES 
Statistical analysis was performed with GraphPad Prism software (GraphPad Software, San Diego, 
CA, USA). Statistical significance (***p < 0.00 ; ** 0.00  ≥ p ≤ 0.0 ; * 0.0  ≥ p ≤ 0.05) was 
determined using an unpaired t-test of at least three experiments.  
 
4.5 BIOINFORMATIC ANALYSIS OF GBM SAMPLES 
Copy number alteration and gene expression profiles of 372 glioblastoma multiforme (GBM) 
samples were downloaded from the TCGA Data Portal (95).  Genes subjected to significant copy 
number alterations (both amplifications and deletions) were extracted from these profiles and 
intersected with a list of 1794 verified RBPs according to InterPro RNA-binding domains (96) and 
a set of novel RBPs identified in a recent work by Castello et al (97). The percentage of samples 
bearing a genomic alteration was extracted from the TCGA Data Portal; the fraction of samples 
exhibiting an over- or under-expression of  each of these RBPs mRNAs was also obtained from the 
same source.  
RBPs subjected to agreeing alterations (i.e., both amplified and overexpressed or both deleted and 
underexpressed) in at least 15% of the samples were eventually selected as interesting candidates.  
Samples bearing genomic alterations of these RBPs loci were intersected with the GBM samples 
grouping as defined in Verhaak et al., (98), to identify potential association of an RBP to one of the 
groups.  Kaplan-Meier survival curves for these candidates were computed by means of the 
REMBRANDT database (99), as the coverage of TCGA samples bearing alterations of these RBPs 
was insufficient. The logrank test p-value was then used to further refine the candidate RBPs list to 
the ones showing a significant survival difference between the amplified/deleted conditions. 
33 
 
A search for regulators and targets of these RBPs was performed  by means of the AURA database 
(100). Eventually, Pearson correlation between the mRNA level of the candidate proteins and 
mRNA level of all genes was computed in order to identify putative novel targets of these RBPs. 
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5. RESULTS 
5.1 Genome-wide analysis of RNA binding proteins expression alterations in GBM identifies 
HuB as a potential tumor suppressor protein. 
To identify potentially altered translational networks in GBM, we started by correlating the 
genomic alteration status and related mRNA levels of RNA-binding proteins in 372 GBM samples 
obtained from the TCGA Data Portal (TCGA-Consortium, 2008). We reasoned that genomic 
amplifications or deletions affecting RBPs and leading to alterations in their protein expression 
levels are likely to impact their target networks in a significant way, potentially perturbing 
fundamental cell processes. To this aim we first identified in our GBM samples the genes subjected 
to significant copy number alterations (both amplifications and deletions) and determined which of 
these genes correspond to RBPs. Of this group, we selected the RBPs whose copy number 
alteration correlated with their altered expression levels in at least 15% of the samples (i.e. genes 
that either showed amplification and were overexpessed in our samples or  were deleted and 
underexpressed). We therefore identified 56 RBPs subjected to agreeing alterations (i.e., both 
amplified and overexpressed or both deleted and underexpressed) in at least 15% of the samples. 
Among the 56 RBPs identified using our parameters, which are listed in Figure 1, we noticed the 
presence of HuB (ELAVL2) as deleted in 48% of the samples and down-regulated in more than 
90% of these. Given the evidence for HuB activity as a differentiation factor in neuronal cells (25, 
64), we reasoned that it may act as an oncosuppressor, therefore suggesting its loss as a required 
mechanism for tumor progression. Therefore, we decided to further investigate the role of HuB in 
glioblastoma multiforme. 
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Figure 6: Genome-wide analysis of RNA binding proteins expression alterations in GBM identifies HuB as 
a potential oncosuppressor protein. (A) Pipeline used to identify altered RBPs in glioblastoma (see Material 
and Methods). Copy number alterations and expression changes (up/down-regulation) were combined to 
obtain RBPs which had concordant changes (e.g. deleted and down-regulated). RBPs conforming to this 
criteria where then filtered for being altered in at least 15% of all considered samples. (B) List of the 56 
RBPs conforming to the criteria used in our bioinformatic analysis. 
 
 
 
A 
B 
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5.2 HuB loss is a frequent event in GBMs. 
Since the bioinformatics analysis of GBM samples (Fig. 6) unraveled a possible role of ELAVL2 
deletion in this cancer, we first tested whether indeed the gene is altered in human GBM biopsies 
by fluorescent in situ hybridization (FISH) analysis. FISH analysis is a standard technique for 
detecting the presence and frequency of chromosomal alterations in heterogeneous samples, such 
as human cancers. As shown in Fig. 7, we found that ELAVL2 was heterozygously deleted in 
about 40% of the GBM samples and was  homozygously deleted in about 8% of the samples. These 
results are in agreement with a putative role of ELAVL2 in GBM. 
Nevertheless, in 9p21.3 the ELAVL2 locus is very close to the CDKN2A locus (1.8 Mb of distance 
between the two loci), with only one intervening other gene locus, that for the DMRTA1 gene. 
Since the p16INK4A/p19ARF proteins, encoded by CDKN2A, are the most powerful and most 
frequently inactivated oncosuppressor loci in cancer in general (86)  and in gliomas in particular (8, 
9), the possibility exists that the ELAVL2 loss is simply an epiphenomenon associated to 
CDKN2A deletion, and does not have a role of modulator of the GBM cell phenotype. 
 
 
 
Figure 7: HuB loss is a frequent event in GBMs.(A) Deletion percentage found in GBM samples with FISH 
technique.(B) Correlation between qPCR  and FISH results. “0” indicates Homozygous deletion. “1” indicates 
Heterozygous deletion. “2” indicates No deletion. On the X axis are reported the FISH results, whereas on Y 
axis are reported the qPCR results. 
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5.3 The patterns of codeletion of the CDKN2A and the ELAVL2 loci in GBM are suggestive 
of a modifier role of ELAVL2 loss in a CDKN2A loss background. 
ELAVL2 and cyclin-dependent kinase inhibitor 2A (CDKN2A) map at the same locus on 
chromosome 9 (9p21.3), at a distance of 1.8 Mb and with only one intervening gene, DMRTA1 
(doublesex and mab-3-related transcription factor-like family A1). Since the p16INK4A/p19ARF 
proteins, encoded by CDKN2A, are powerful and frequently inactivated oncosuppressor loci in 
cancer in general (86) and in gliomas in particular (8, 9), the possibility existed that the ELAVL2 
loss is simply an epiphenomenon associated to CDKN2A deletion, and does not have a role of 
modulator of the GBM cell phenotype. 
Therefore, we became interested in understanding the structure of the deletion spanning  the 
CDKN2A and the ELAVL2 loci, by studying as many GBM samples as possible. To this aim, we 
initially exploited the publicly available data related to The Cancer Genome Atlas (TGCA) core 
GBM samples (n=372), endowed with high resolution genomic imbalance profiles obtained by 
aCGH . Subsequently, we examined the same two loci by quantitative PCR (qPCR) on genomic 
DNA of an independent cohort of 233 consecutive GBM samples diagnosed between 2006 and 
2009 at the Verona Borgotrento Hospital (Verona, Italy) by the same pathologist. Figure 8A reports 
synoptically the results of both analyses. We found that about half of the tumors (47% TGCA and 
42% Verona samples) did not present any gain or loss in the CDKN2A and ELAVL2 loci. 
Deletions of ELAVL2 in the presence of wild type CDKN2A were basically absent in both sample 
groups, while CDKN2A monoallelic loss was accompanied in about a quoter of cases (19% TGCA 
and 25% Verona samples) by an intact ELAVL2, and less frequently (8% TGCA and 6% Verona 
samples) by a corresponding monoallelic loss of ELAVL2. Homozigous deletion of CDKN2A, the 
lesion at the basis of the oncosuppressor activity of p16INK4A and p19ARF, was present in about 
a quarter of the total samples, (26% TGCA and 38% Verona samples) of which 50-61%, depending 
on the sample group, were not deleted at all at the ELAVL2 locus, which instead was 
correspondingly deleted in the remaining cases (10%-20% of the total samples). 
The only discrepancy between the two groups, which showed a remarkable agreement considering 
the different sampling and the different detection techniques used in evaluating the DNA copy 
number, was the presence, only in the Verona samples, of an high frequency of homozygous 
CDKN2A deletions in combination with heterozygous ELAVL2 deletions (8%). Therefore, it 
seems that the 1.8Mb region of 9p21.3 having these two loci at the extremes is deleted in GBMs 
following two patterns: the first and prevalent pattern is a focused deletion involving the CDKN2A, 
but not the ELAVL2 locus, while the second is a deletion extended to this second gene, found 
numerically in about 50% of the total CDKN2A deleted samples. 
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To test the possibility that this deletion pattern results from a random distribution of deletion 
margins and is therefore not the result of a double selective pressure on CDKN2A and ELAVL2, 
we looked in our GBM samples for the existence of double focal deletions affecting these two 
genes. To this aim, qPCR analysis testing the presence of two intervening regions (INV1 and 
INV2) between CDKN2A and ELAVL2 was performed on the 58 GBM samples bearing homo- 
and/or heterozygous deletions at both loci. We found that in 12 samples (Fig. 8B) the continuity of 
the deletion between CDKN2A and ELAVL2 is interrupted. Therefore, two independent focal 
deletion events occurred in 20 % of the GBM samples bearing homo- and/or heterozygous deletion 
at CDKN2A and ELAVL2 ,rendering the double focal deletion a rare, but recurrent event. 
 
Figure 8: Deletion of ELAVL2 in GBM occurs frequently and is always associated with CDKN2A deletion; 
however, in a subset of samples is the results of two independent deletion events.(A) Frequency of 
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deletions at the CDKN2A and ELAVL2 loci in the TGCA GBM core dataset (lower panel) detected by aCGH 
and from paraffin-preserved GBM samples from the Verona’s hospital (upper panel) detected by qPCR. 
Each gene is depicted by two horizontal bars; a black bar represents the presence of the allele, whereas a 
grey bar represents the absence of allele.(B) Deletion profiles of CDKN2A, ELAVL2 and the two intervening 
regions (INV1 and INV2) for samples bearing deletions of both CDKN2A and ELAVL2, analysed by qPCR. A 
black bar represents the presence of the allele, whereas a grey bar represents the absence of allele. 
 
 
5.4 HuB modulation in U87MG cells and HuB reconstitution in glioma initiating cells indicate 
that HuB suppresses glioma cell migration and invasion. 
We then looked for suitable cell models to investigate the effects of the HuB protein in a CDKN2A 
null glioma background. We initially employed U87MG cells, a commonly used glioma cell line, 
and we genotyped it for the two loci of our interest. U87MG cells resulted to be homozygously 
deleted for CDKN2A and heterozygously deleted for ELAVL2 (Fig. 9A1). Downregulation of HuB 
by a lentivirally-transduced shRNA reduced its expression to more than 80% (Fig. 9A2), producing 
an HuB knock-down model. The measure of cell motility by both a scratch test (87) and by a 
Boyden chamber assay coherently demonstrated a statistically significant increase with reduction 
of HuB, which was revealed in a more pronounced way (increase of more than 60%) through the 
Boyden chamber (Fig. 9B1 and 9B2). In the same ELAVL2 heterozygous background we also 
stably overexpressed HuB by lentiviral infection, obtaining a sharp decrease of cell motility in the 
Boyden chamber (Fig. 9B3). 
Since stabilized cell lines are not considered entirely recapitulating glioma cell behavior (13), we 
also genotyped a number of primary glioma initiating cells (GICs) grown in a defined standard 
FGF2/EGF medium (84). We choose  GIC#030616, whose cells are homozigously deleted for both 
CDKN2A and ELAVL2 (Fig. 9A3), and therefore suitable to rescue HuB expression. Using this 
model, we could perform full reconstitution of HuB in a CDKN2A null background (Fig. 9A4-6), 
which again resulted in clear decrease in motility (Fig. 9B4). We therefore concluded that loss of 
HuB expression, both monoallelic and biallelic, is able in glioma cells which have lost p16INKA 
and p19ARF expression to markedly reduce motility. Moreover, there is an inverse relationship 
between this cell phenotype, which is highly relevant to gliomatogenesis, and HuB expression. 
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Figure 9: ELAVL2 over-expression in two neuronal cell lines leads to a reduction in cell migration. (A) U87 
cells are heterozygous deleted for ELAVL2 and can be knock-down, whereas GICs are homozygous deleted 
for ELAVL2 and can be overexpressed. In A1-4 the internal control represents conditions of no deletion. 
Experiments were performed from three biological replicates, each one consisting of three technical 
replicates.  Error bars indicate standard error of the mean (SEM). Asterisks indicate P<0.05 as determined 
by unpaired Student’s  t-test. (A1) CDKN2A and ELAVL2 copy number in U87 cells, quantified on genomic 
DNA using qPCR. U87 are homozygous deleted for CDKN2A and heterozygous deleted for ELAVL2. (A2)  
ELAVL2 expression in U87 cells knock-down (U87 sh-HuB) and control cells (U87 sh-scr), quantified with 
qPCR. (A3) ELAVL2 protein level in U87 sh-scr and in U87 sh-HuB as determined by immunoblotting. (A4) 
Quantification of the immunoblot shown in A3. (A5) CDKN2A and ELAVL2 copy number in GICs, quantified 
on genomic DNA using qPCR. GICs are homozygous deleted  for both CDKN2A and ELAVL2. (A6) ELAVL2 
expression in GICs  after over-expression (GICs-HuB) and in control cells (GICs-CTR), analyzed by qPCR . (A7) 
ELAVL2 protein level in GICs-HuB  and in GICs-CTR as determined by immunoblotting. (A8) Quantification of 
the immunoblot shown in A7. (B) ELAVL2 knock-down affects migration. In B1-3 U87 sh-HuB indicates 
ELAVL2 knockdown, whereas U87-HuB indicates ELAVL2 over-expression. (B1) Migration analysis of U87 
cells performed with Scratch test. (B2-3) Migration analysis of U87 cells performed with Cell Migration 
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Assay. (B4) Migration analysis of GICs performed with Cell Migration Assay. GICs-HuB indicates ELAVL2 
over-expression. All experiments were performed from three biological replicates, each one consisting of 
three technical replicates. Error bars indicate standard error of the mean (SEM). Asterisks indicate P<0.05 as 
determined by unpaired Student’s  t-test. 
 
Finally, we checked in the same cell models if HuB had an effect on cell invasivity, by performing 
the Boyden chamber assay with a matrigel layer. U87MG cells down-regulated for HuB revealed a 
not statistically significant tendency to increased invasion (Fig. 10A left), while U87MG  cells 
overexpressing HuB  displayed a 60% reduction in their invasive capabilities (Fig. 10A right). The 
difference in extent of the two results could be justified by the already low level of constitutive 
HuB expression in U87MG cells, because of expression of a single allele, and by the partial HuB 
suppression by shRNA (see Fig. 9A2). Reconstitution of HuB expression in GIC#030616 cells 
resulted in a sharp decrease in invasivity, comparable  to the effect of HuB over-expression 
observed in U87MG cells (Fig. 10B). 
 
 
 
Figure 10: ELAVL2 over-expression decreases invasion capabilities in GICs and U87 cells. (A) The panel 
shows the effects of ELAVL2 knock-down (U87 sh-HuB; left) and over-expression (U87-HuB; right) on the 
invasion capabilities of U87 cells, as determined by the Cell Invasion Assay (see Material and Methods).  (B) 
Effects of ELAVL2 over-expression (GICs-HuB) on the invasion capabilities of GICs, as determined by the Cell 
Invasion Assay. All experiments were performed from three biological replicates, each one consisting of 
three technical replicates. Error bars indicate standard error of the mean (SEM). Asterisks indicate P<0.05 as 
determined by unpaired Student’s  t-test. 
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5.5 Loss of HuB expression increases the degree of stemness in glioma cells. 
Having observed a reduction in migration and invasiveness upon HuB expression in both 
glioblastoma cell line models, we further tested in the same lines the ability of HuB to modulate 
neurosphere formation in a defined medium, a feature associated with glioma aggressiveness (94). 
U87MG cells increased neurosphere formation upon HuB down-regulation, and strongly decreased 
it by HuB up-regulation (Fig. 11A, top panel). Reconsitution of HuB expression in GICs 
determined a drastic decrease in the ability to form neurospheres, and these neurospheres were of 
smaller size as determined by measuring the average diameter and area with an high-content 
imaging system (Fig. 11A, middle and lower panels). 
These experiments clearly indicate that HuB contribute in reducing the cells proliferation abilities 
in both glioma models. Neuronal development is promoted by several transcription factors 
including of the stemness markers nestin and SOX2 (89-94). Therefore, we tested the expression 
levels of these two  stemless marked upon HuB down-regulation in U87 cells and expression in 
GICs. As shown in Fig. 11B,  HuB down-regulation in U87MG cells resulted in a net increase of 
the expression of nestin and SOX2, whereas HuB expression in the HuB-deficient GICs decreased 
both markers (Fig. 11B). 
Overall, these results support the hypothesis that HuB acts as an oncosuppressor, reducing the 
cell’s ability to proliferate. This repression activity is mediated, at least in part, by a reduction in 
the expression of stemness genes, such as nestin and SOX2.  
 
43 
 
 
Figure 11: ELAVL2 overexpression in GICs and U87 cells leads to a drastic decrease in neurosphere 
formation capabilities and lower levels of stemness markers.(A) ELAVL2 over-expression decreases the 
capacity to form neurospheres. Upper panel Effects of ELAVL2 knock-down (U87 sh-HuB; left) and over-
expression (U87-HuB; right) on the ability to form neurospheres in U87 cells, as determined by the 
Neurosphere assay (see Material and Methods). Middle panel Effects on neurosphere formation of ELAVL2 
over-expression (GiCs-HuB; green) or over-expression of a control plasmid (GICs-CTR; red) in GICs as 
determined using the PerkiElmer Operetta High-content Screening System (see Material and Methods). Ten 
random fields and a blow up of a representative field are shown for each condition. Lower panel  Number 
(left), area
 
(middle) and diameter (right) of neurospheres from the experiment shown in the middle figure 
as obtained from the Operetta software. All experiments were performed from three biological replicates, 
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each one consisting of ten technical replicates. Error bars indicate standard error of the mean (SEM). 
Asterisks indicate P<0.05 as determined by unpaired Student’s  t-test.(B) ELAVL2 levels affects stemness in 
GICs and U87 cells. Left panel Nestin (NES) and SRY (sex determining region Y)-box 2 (SOX2) expression 
levels in ELAVL2 knock-down U87 cells (U87 sh-HuB) and in control cells (U87 sh-scr) as determined by 
qPCR.  Right panel NES and SOX2 expression levels in GICs overexpressing ELAVL2 (GICS-HuB) and in control 
cells (GICs-CTR) as determined by qPCR. All experiments were performed from three biological replicates, 
each one consisting of three technical replicates. Error bars indicate standard error of the mean (SEM). 
Asterisks indicate P<0.05 as determined by unpaired Student’s  t-test. 
 
 
5.6 HuB controls the expression of genes involved in cell adhesion and motility. 
Down-regulation of HuB in U87MG cells reduced its expression to more than 80% (Fig. 9A2), 
giving the possibility to investigate the whole network of genes regulated by HuB in glioblastoma. 
Therefore, we performed an array-based translatome profiling by hybridizing polysomal mRNAs 
from U87MG sh-HuB or control cells (U87MG sh-scr) to a whole human genome microarray and 
identified all genes differentially present on polysomes between the two samples. We choosed to 
determine the changes in the ribosomally-loaded mRNAs instead of the total mRNA changes, 
because there is usually a wide degree of uncoupling between the two (88) and because we were 
interested in assessing the effects of an RBP deleted in glioma on translational control, the level of 
gene expression regulation closest to the phenotype. Besides a strong signature related to cytokine 
activation and another to angiogenesis, we found that down-regulation of HuB affected major 
processes related to cell movements (cell adhesion, regulation of cell migration, locomotor 
behaviour and chemotaxis), for a total of 123 genes, together with the well-known phenomenon 
already associated to HuB, neuronal differentiation (see Figure 12). 
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Figure 12: HuB down-regulation impacts on functions and processes relevant to cancer progression. The 
figure displays the biological processes and functions enriched in genes differentially expressed at the 
polysomal level following HuB down-regulation. Genes related to each term are displayed on the right side 
with the related enrichment p-value. 
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5.7 The p21 tumor suppressor is translationally enhanced by HuB in mouse neural tube cells. 
HuB expression in glioma stem cells resulted in a marked inhibition of clonality, i.e. an inhibition 
of stem cell proliferation, suggesting that it might alter cell-cycle regulation. Cyclin-dependent 
kinase inhibitor 1 (p21/WAF), is a known tumor suppressor gene which is indirectly 
transcriptionally targeted in glioblastomas by both inactivating mutations in TP53 and 
overexpression of BMI1 (116, 117). To test whether p21 could be a target of HuB in condition of 
normal neuroblast proliferation we used H2b2T cells, a line of neural tube neuroblasts derived by 
transgenic mice expressing the SV40 Large T antigen, and therefore able to growth indefinitely by 
the ability to bypass the G1-S checkpoint. They express the ubiquitous ELAVL protein HuR, but 
not the neuronal members of the family (HuB, HuC, HuD), therefore they are an ideal system to 
study HuB effects without confounding variables. We transiently transfected H2b2T cells with 
mouse HuB and checked the steady-state levels of p21 mRNA (Fig. 13A) by qRT-PCR with a 
probe recognizing both annotated transcript variants, which differ only for an alternative 5’UTR. 
Since we did not detect any changes in p21 mRNA levels, we determined the levels of the two 
transcript variants by qPCR using primers specific to the two 5’UTRs as well as the common 
3’UTR (Fig. 13B), finding again no significant variation in the levels of both mRNA isoforms, in 
the absence or presence of transfected mouse HuB. We concluded that HuB has not effects on the 
steady state levels of the two annotated isoforms of p21 mRNA in neural tube cells. Then, we 
determined the levels of p21 protein and found a reproducible increase upon HuB over-expression 
(Fig. 13C). These results suggest that the increase of p21 protein levels induced by transient HuB 
expression is likely due to a translational enhancement exerted on the p21 mRNA. 
To further investigate this activity, we generated H2b2T cells that stably-express HuB (H2b2t st-
HuB) or control cells (H2b2t st-CTR) and transiently transfected with luciferase reporters bearing 
the two variants of the murine p2  5’UTRs inserted upstream of the coding sequence as well as the 
p2  3’ UTR inserted downstream of the CDS.  Luciferase activity from the firefly luciferase 
chimeric reporters was measured in cells stably-expressing HuB or in control cells that do not and 
the results were normalized to the renilla luciferase activity obtained from a co-transfected plasmid. 
The luciferase activities of the reporters bearing either the p2  3’UTR or the p2  5’UTR of 
transcript variant 1 were significantly increased in the presence of HuB, whereas no effects were 
seen with the p2  5’UTR of transcript variant 2 (Fig. 13C). Therefore, we conclude that the 5’ 
UTR variant   and the 3’UTR of p2  are targeted by HuB to determine an increased p2  translation 
in neural tube neuroblasts. 
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Figure 13: p21 is regulated at post-trascriptional level by HuB, through 5’ and 3’UTR binding.(A) Over-
expression of HuB in H2b2T cells. Left panel: qPCR with for HuB and p21 mRNA from H2b2T cells 
transiently-transfected with an expression plasmid for HuB (blue histograms) or control cells transfected 
with an empty plasmid (grey histograms). The high standard deviation in HuB expression levels is due to the 
intrinsic variability of transient transfection. The data represents four biological replicates, each one 
consisting of three technical replicates. Middle panel: HuB protein and p21 protein levels in H2b2T cells 
transiently-transfected with an expression plasmid for HuB (H2b2T-HuB) or  an empty plasmid (H2b2T-CTR). 
The picture was taken using by ChemiDoc XRS+ System (Bio-Rad, 170-8265). As loading control, the same 
blot was probed for -Tubulin (top). (B) Effects of HuB overexpression on p21 mRNA and protein levels. Left 
panel: qPCR on cells stably-expressing HuB (H2b2Tst-HUB; blue histograms) or control cells (H2b2Tst-CTR; 
grey histograms), using primers specific for different regions of the p21 mRNA: results from the first 
biological replicate (four biological replicates, each one consisting of three technical replicates). (C) HuB up-
regulates p21 protein expression interacting with the p21 3’UTR as well as the 5’ UTR of one of its transcript 
variants. Panels: Luciferase activity of reporters containing the p21 3’UTR (left Panel), p21 5’UTR-v1 (middle 
Panel) or p21 5’UTR-v2 (Right Panel) fused to the coding sequence of Luc2 gene, transiently transfected into 
H2b2T-HUB (blue histograms) or H2b2T-empty (grey histograms) cells. The luciferase values represent a 
ratio between the firefly luc and the renilla luc and represent the average of three replicates. Error bars 
indicate standard error of the mean (SEM). Asterisks indicate P<0.05 as determined by unpaired Student’s  
t-test. 
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6. DISCUSSION 
 
The results presented here demonstrate that HuB is deleted in a fraction of GBM patients and that                              
such deletion is correlated with a more aggressive tumorigenic phenotype. These results are 
relevant because, untill now, it is the first study involving HuB and cancer. 
HuB is a member of the ELAV family, a group of RNA binding proteins involved in neuronal 
differentiation. Among the four ELAV proteins, which share high levels of sequence and structure 
identity, the ubiquitously expressed HuR protein is the best studied. HuR is often over-expressed in 
human gliomas and its pharmacological inhibition results in glioma cell growth inhibition 
suggesting that HuR-mediated dysregulation of protein stability is necessary to sustain the rapid 
growth of this type of cancer (119). It appears to exert its oncogenic effects via stabilization of a 
subset of mRNAs, such as IL-8, VEGF and all bcl-2 family members (120, 121). 
In this study we exploited the public data on TGCA Data Portal (TCGA-Consortium, 2008) to 
correlate the genomic alteration status and related mRNA levels of RNA-binding proteins in 372 
GBM samples,  discovering that HuB is deleted in 48% of the samples and down-regulated in more 
than 90% of these. Given the evidence for HuB activity as a differentiation factor in neuronal cells 
(25, 64), we reasoned that it may act as an oncosuppressor. This result was further confirmed with 
FISH and qPCR techniques, performed on 233 DNA samples of GBM. We found that ELAVL2 
was heterozygously deleted in about 40% of the GBM samples and was homozygously deleted in 
about 8% of the samples using FISH technique; whereas using qPCR it was deleted respectively in 
27%  and 11 % of the samples. 
Nevertheless, in 9p21.3 the HuB locus (represented by ELAVL2) is very close to the CDKN2A 
locus (1.8 Mb of distance between the two loci), with only one intervening gene: DMRTA1, which 
is supposed to be involved in sexual development but not with cancer 
(http://www.phosphosite.org/proteinAction.do?id=1290356&showAllSites=true). Since the 
p16INK4A/p19ARF proteins, encoded by CDKN2A, are the most powerful and most frequently 
inactivated oncosuppressor loci in cancer in general (86)  and in gliomas in particular (8, 9), the 
possibility exists that the ELAVL2 loss is simply an epiphenomenon associated to CDKN2A 
deletion, and does not have a role of modulator of the GBM cell phenotype. To this aim, qPCR 
analysis testing the presence of two intervening regions (INV1 and INV2) between CDKN2A and 
ELAVL2 was performed on the 58 GBM samples bearing homo- and/or heterozygous deletions at 
both loci. We found that in 12 samples the continuity of the deletion between CDKN2A and 
ELAVL2 is interrupted. Therefore, two independent focal deletion events occurred in 20 % of the 
GBM samples bearing homo- and/or heterozygous deletion at CDKN2A and ELAVL2 ,rendering 
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the double focal deletion a rare, but recurrent event. This finding strengthens the notion that in a 
fraction of GBM patients, HuB loss contributes to malignant tumour progression.  To our 
knowledge, this is the first report suggesting that a selective pressure exists to eliminate two 
tumours suppressor genes independently in such a small genomic region. To test the hyphothesis 
that HuB acts as an oncosuppressor, we modulated HuB protein levels in U87MG cells line and 
expressed it in glioma initiating cells. The results demonstrate that HuB expression suppresses 
glioma cell migration and invasion, whereas other studies demonstrated that  ectopic misexpression 
of HuB in the mouse neural tube determines the appearance of neuronal markers (55).                                  
Finally we demonstrate that loss of HuB in the same cell models increases the degree of stamness, 
and it was further confirmed testing the expression levels of Sox2 and Nes , two well 
known stemness markers (89, 94). Taken together these results support the hypothesis that HuB 
acts as an oncosupressor reducing cell ability to proliferate and invade. 
To investigate the whole network of genes regulated by HuB in GBM, we performed an array-
based translatome profiling by hybridizing polysomal mRNAs from U87MG sh-HuB or control 
cells. We found that down-regulation of HuB affected major processes related to cell movements, 
such as cell adhesion, regulation of cell migration, locomotor behaviour and chemotaxis and, 
according  with the current literature,  neuronal differentiation process. These results are in 
agreement with the previous in vitro experiments. 
The most extensively studied member of ELAVL family is HuR. It is expressed early in 
neurogenesis (29) and acts by stabilizing a number of target mRNAs, mainly via interaction with a 
well characterized sequence motif in their 3’ UTRs (44). This motif is present in many short-lived 
mRNAs and is called the de-stabilizing adenylate/uridylate-rich element (ARE). Recent findings 
showed that HuR mRNA exists in three different isoforms, two of which are expressed in neurons: 
2.4-kb isoform that is also ubiquitously expressed in other tissue types, and a 6.0-kb isoform that is 
induced during neuronal differentiation and appears to be neuron-specific. Neuronal HuB, HuC and 
HuD, as well as HuR itself can bind the 2.4-kb mRNA polyadenylation site, and when 
overexpressed, they can induce expression of an extended HuR 3’ UTR that is translationally 
suppressed. This suggests a model where the regulation of HuR protein expression allows neurons 
to post-transcriptionally regulate mRNAs encoding factors required for proliferation versus 
differentiation to facilitate neuronal differentiation (122). In the light of the above findings, it is 
possible to speculate that upon the HuB loss in GBM patients, HuR expression cannot be 
efficiently down-regulated, which keeps cells locked in a high stemness state. To understand if this 
is the case, future work will focus on investigating the expression level of the different HuR 
isoforms upon HuB over-expression in GICs. 
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In search of HuB mRNA targets that would explain the functional findings, p21 was identified. We 
found that the 5’ UTR variant   and the 3’UTR of p21 are targeted by HuB  determining an 
increased p21 translation in neural tube neuroblasts. This is consistent with other studies that 
already identified p21 as targets of HuD (123) and HuR (71, 108), however, different cell cycle 
regulatory mechanisms appear to exist depending on stimuli (124).  p21 is a key regulator of cell 
cycle and  deletion of p21 in mice produces a proliferation burst of neural stem cells in the 
forebrain, followed by exhaustion and depletion (125), supporting the notion that p21 stabilisation 
by HuB could be key to induce neuronal differentiation and cell cycle arrest. 
It will be interesting to analyze in detail the expression of HuR and other potential  protein targets 
of HuB. Although it was clear from our result that a previously unrecognized lesion, the loss of the 
ELAVL2 locus coding for the neural RNA binding protein (RBP) HuB, could impact SVZ 
neurogenesis, interfering both with the exit from cell cycle and with the first phase of neuronal 
differentiation, and consequently being central to gliomagenesis in a fraction of GBM tumours. 
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Figure A.1: Evaluation of copy number of MECP2 in males and females DNA samples using qPCR. (A) F1 
(pink bar) is a female, M1 and M2 (red bars) are males. Pink bar is twice of red bars meaning that MECP2 is 
present in two copies.  (B) Pink  expression curve is a female sample, whereas the red expression curves 
are male samples. Pink curve is earlier than red curves , meaning that the amount of DNA is higher. 
8. APPENDIX 
 
Copy number alterations (CNAs) can be detected by qPCR using SYBR-GREEN 
To validate the capacity of SYBR-GREEN qPCR method in discriminating copy number 
alterations (CNA), an analysis on MECP2, a gene present on chromosome X, was performed on 
genomic DNA of males and females. SNRPF and CTDSP1 were used as reference genes. The 
internal control used for this analysis was a female sample. As it can be shown in Figure A.1 the 
analysis worked perfectly: the amount of MECP2 gene is twice in female sample compared to male 
samples. The SYBR-GREEN qPCR method worked and was used to evaluate CNAs. 
 
As the data show, the level of MECP2 in the female is twice the level in males (see Figure A.1.A), 
meaning that MECP2 gene is present in two copies in female samples compare the male samples. 
Observing the qPCR curves (Figure A.1.B), the pink curve (female curve) is first to the red curves 
(male curves) meaning that the amount of DNA is higher in female sample compare the male 
samples. 
This analysis confirmed that qPCR, performed with SYBR-GREEN and gene specific primers, can 
detect copy number alterations. Each range of the Table 9 was set fitting a median value and , from 
that point, minimum closed extremities were set to maximize the evaluation, improving the 
accurancy. For each samples, the value corresponding to Unfold Expression on CFX Manager TM 
Software 184-5000 (Version 3.0, Bio-Rad) was compared to this scale (Table A.1) to detect CNAs. 
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Table A.1: Scale used to evaluate copy number variations. The value relative to unscaled expression value  
are compared with this scale to determine the allele’s number. 
COPY NUMBER RANGE RESULT 
0 -0,24 ‒ 0 ‒ 0,24 HOMOZYGOUS DELETION 
1 0,25 ‒ 0,5 ‒ 0,75 HETEROZYGOUS DELETION 
2 0,76 ‒ 1 ‒ 1,25 NORMAL 
3 1,26 ‒ 2 ‒ 1,75 3 COPIES 
4 1,76 ‒ 2,5 ‒ 2,25 4 COPIES 
 
 
 
 
Figure A2: From A to E panels are reported the standard curve for each couple of primers and the relative 
values of efficiencies (estimated from the slope (m) : E = 10^ (-1/m) - 1), which are almost identical and 
therefore amplifying at the same rate, meaning an accurate quantification of CNV. 
